RE:Phase 2/3 OV company Genelux trades at US$35.00In Genelux's Phase 2 clinical trial of 27 heavily pretreated patients with platinum-resistant or -refractory ovarian cancer (PRROC [platinum-resistant (n=14) or platinum-refractory (n=13)] and median 4 prior lines of therapy, Olvi-Vec followed by platinum-based chemotherapy ± bevacizumab as immunochemotherapy demonstrated objective response rate (ORR) of 54% and a median progression-free survival (PFS) of 11.0 months with a manageable safety profile.
On June 5, 2023 ONCY reported results from BRACELET-1, a randomized phase 2 trial in HR+/HER2- metastatic breast cancer, which include data featured in an oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with single agent pelareorep + chemotherapy, as opposed to Genelux's combination therapy of Oli-Vec + chemotherapy ± bevacizumab : Pelareorep-paclitaxel combination reduced risk of disease progression by 71% (hazard ratio of 0.29) compared to paclitaxel monotherapy
37.5% confirmed overall response rate with pelareorep-paclitaxel vs. 13.3% with paclitaxel monotherapy
12-month progression-free survival rate of 32.8% for pelareorep-paclitaxel compared to 0% for paclitaxel monotherapy and 0% for pelareorep-paclitaxel-avelumab
https://ir.oncolyticsbiotech.com/press-releases/detail/601/oncolytics-biotech-announces-updated-randomized-phase-2
Oncolytics' HR+/HER2- breast cancer program now phase 3-ready and advancing to a registrational study of pelareorep-paclitaxel combination